The cyclic AMP paradox in pulmonary fibrosis: context is everything…
- 16 October 2025
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (4) , 2501382
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- A deep generative model for deciphering cellular dynamics and in silico drug discovery in complex diseasesNature Biomedical Engineering, 2025
- Nerandomilast in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2025
- Nerandomilast in Patients with Progressive Pulmonary FibrosisNew England Journal of Medicine, 2025
- Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals ubiquitin promotes pulmonary fibrosis in chronic pulmonary diseasesScientific Reports, 2024
- EPAC1 enhances brown fat growth and beige adipogenesisNature Cell Biology, 2024
- Pulmonary fibrosis: Emerging diagnostic and therapeutic strategiesMolecular Aspects of Medicine, 2023
- Fibromine is a multi-omics database and mining tool for target discovery in pulmonary fibrosisScientific Reports, 2021
- cAMP and Epac in the regulation of tissue fibrosisBritish Journal of Pharmacology, 2012
- The cyclic AMP effector Epac integrates pro- and anti-fibrotic signalsProceedings of the National Academy of Sciences, 2008
- Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartmentsProceedings of the National Academy of Sciences, 2004